A case of metastatic castration-resistant prostate cancer by abiraterone treatment.
10.11817/j.issn.1672-7347.2015.06.019
- Author:
Liuxun LI
1
;
Zhi LONG
1
;
Leye HE
1
Author Information
1. Department of Urology, Third Xiangya Hospital, Central South University, Changsha 410013, China.
- Publication Type:Case Reports
- MeSH:
Androstenes;
therapeutic use;
Bone Neoplasms;
drug therapy;
secondary;
Disease Progression;
Humans;
Male;
Prostate-Specific Antigen;
blood;
Prostatic Neoplasms, Castration-Resistant;
drug therapy;
pathology
- From:
Journal of Central South University(Medical Sciences)
2015;40(6):688-692
- CountryChina
- Language:Chinese
-
Abstract:
We reviewed and analyzed the clinical data for a patient with metastatic castration-resistant prostate cancer (mCRPC) from September, 2009 to December, 2014. After the treatment with abiraterone, patient's performance status improved, pain relieved, total prostate specific antigen (tPSA) and free prostate specific antigen (fPSA) markedly decreased. tPSA or fPSA fluctuated between
30 and 50 ng/mL or between 10 and 20 ng/mL. MRI showed the left peripheral zone reduced. MRI and bone single photon emission computed tomography (SPECT) scan showed no new metastasis. These results indicated that application of abiraterone for patient with mCRPC not only decreased prostate specific antigen (PSA) levels and tumor volume, but also blocked bone metastasis progression and enhanced pain relief.
